Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The University of Edinburgh has developed new methods for cleaning surgical instruments, which completely remove protein contamination, including prions - the infectious agents that cause Creutzfeldt-Jakob Disease (CJD) in humans. More
A suite of highly specific, proprietary bacterial drug targets in staphylococcus aureus, that can be used individually or as a group to develop small molecule or peptide drug leads with powerful anti-infectives properties. More
Pharmaceutical composition based on Mutants created by insertions and deletions of Ezrin More
The first functional test for simultaneous identification and validation of miRNA targets, which is easy to use and offers rapid results with guaranteed accuracy. More
An in vitro hepatitis C virus (HCV) replication system that is capable of producing viral particles in a culture medium More
The University of Edinburgh, in collaboration with the SNBTS, Roslin Institute Neuropathogenesis Unit, and the University of Strathclyde, has developed an antibody that can distinguish abnormal PrP (PrPSc) from the normal cellular form (PrPC) More
Kemin Pharma has identified new bicyclic carbohydrate based lead molecules with good and selective antiviral activity against cytomegalovirus (CMV) in humans More
Monoclonal antibody for a novel HIV protein with potential diagnostic, prognostic, and therapeutic uses. More
Novel radiolabeled compounds for radioimaging (e.g., positron emitting tomography (PET), Computed Tomography (CT), PET/CT and Single Photon Emission Tomography (SPECT)) and/or radiotherapy More
This technology overcomes the amount of time required to culture and identify pathogens, using standard collection methods, is able to identify over 98% of relevant pathogens, and is a fully automated process More
Your selection
Browse By
- Industry sector
- Antibody-based diagnostics
- Biomarker-based diagnostics
- CAT
- Genetic diagnostics
- Imaging
- MRI
- Nuclear medicine
- Other
- Self-test systems
- Supplies
- Test systems
- Ultrasound
- X-ray
- Therapeutic target
- Bacteria or virus
- Bioterrorism
- Diseases
- Hepatitis (other)
- Nosocomial infections
- Parasitic diseases
- Treatments
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us